Skip to content

Sex Differences in E-Cigarette Perception

Sex Differences in E-Cigarette Perception: Study 2

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07398976
Enrollment
60
Registered
2026-02-10
Start date
2026-07-30
Completion date
2027-04-01
Last updated
2026-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E-cigarette Use, Nicotine Dependence

Keywords

Sex Differences, Females, E-cigarettes, Menthol, Nicotine, Vaping

Brief summary

This study examines differences between males and females in the appeal and addiction potential of menthol flavored e-cigarettes with and without nicotine.

Detailed description

The goal of this protocol is to investigate how sex differences in response to menthol and nicotine influence product preference and choice. In this proposal, participants will be exposed to menthol non-nicotine and nicotine containing e-cigarettes and product preference and choice will be examined in a paradigm where a menthol nicotine-containing e-cigarette is progressively more difficult to earn, and a menthol non-nicotine e-cigarette is available at a low, fixed cost. Additionally, it will be investigated how menthol e-cigarettes with and without nicotine impact reward, appeal, and sensory effects in an initial sampling session (secondary and exploratory outcomes).

Interventions

OTHERNicotine Level 1 (0mg/ml)

Menthol with be paired with 0mg/ml nicotine in an e-cigarette

OTHERNicotine Level 2 (36mg/ml)

Menthol with be paired with 36mg/ml nicotine in an e-cigarette

OTHERNicotine Level 3 (59mg/ml)

Menthol with be paired with 59mg/ml nicotine in an e-cigarette

Sponsors

Yale University
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

Participants will test three e-cigarettes in containing varying levels of nicotine and menthol in a sampling session in Lab 1 in a double blinded randomized order. Investigator and research assistant (i.e., care provider) will know the nicotine concentrations and menthol level of the three e-cigarettes, but will be blinded to the order of presentation/participant. For Lab 2, two of the three e-cigarettes are compared in a choice task. The participant will not know the nicotine or menthol of the e-cigarettes (but as they will be labeled the same as Lab 1, so will have prior experience with them). The investigator and research assistant will know the e-cigarettes as a function of the study design.

Intervention model description

Study is a within subject design. All participants are exposed to the same three e-liquids in randomized order under double-blinded conditions in the Lab 1 sampling session. In Lab 2, two of the three e-liquids (the same two across participants) are tested in a concurrent choice session.

Eligibility

Sex/Gender
ALL
Age
21 Years to 44 Years
Healthy volunteers
Yes

Inclusion criteria

* Able to read/write in English * Current cigarette smoking * Prior e-cigarette exposure * Biochemically verified cigarette use * Not trying to quit tobacco use

Exclusion criteria

* Significant medical concerns that would increase study risk * Use of psychoactive drugs unless prescribed and stable * Allergy to menthol or other e-liquid ingredients * Dislike of menthol * Pregnant, trying to get pregnant, breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Proportion of ChoicesFor the 3 hour period of the Lab 2 preference taskDifferences in proportion of choices for the two menthol e-cigarette for males and females in the Lab 2 preference task
BreakpointDuring the 3 hour period of the Lab 2 preference taskDifference in highest point of the progressive ratio schedule obtained between males and females

Secondary

MeasureTime frameDescription
RewardImmediately (~2 minutes) after e-cigarette exposures in Lab 1Difference in scores (range: 0-100) of the Liking/Wanting Subscale of the Drug Effects Questionnaire

Countries

United States

Contacts

CONTACTDanielle R Davis, PhD
danielle.davis@yale.edu2039747607
PRINCIPAL_INVESTIGATORDanielle R Davis, PhD

Yale University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 3, 2026